🗞️ Why in News India launched a nationwide free HPV vaccination drive on February 28, 2026, targeting 14-year-old girls. India records over 1.2 lakh new cervical cancer cases and approximately 80,000 deaths annually — the highest absolute burden globally.
The Editorial Argument
The Hindu editorial argues that while the national HPV vaccination campaign is a landmark public health intervention, vaccination alone is insufficient. India must simultaneously scale up cervical cancer screening (currently covering less than 2% of eligible women), address rural-urban disparities, tackle vaccine hesitancy, and build treatment infrastructure to meet the WHO 90-70-90 targets by 2030.
India’s Cervical Cancer Burden
| Metric | Data |
|---|---|
| New cases annually | ~1.2 lakh (1,23,907 — Globocan 2022) |
| Annual deaths | ~79,000 |
| India’s share of global cases | ~23% |
| Leading cause of cancer death among women (India) | 2nd (after breast cancer) |
| Screening coverage | <2% of eligible women |
| HPV prevalence (high-risk types) | ~5-8% among women aged 15-59 |
HPV Vaccination — The National Programme
| Feature | Detail |
|---|---|
| Launched | February 28, 2026 |
| Target group | Girls aged 14 years |
| Vaccine | Made-in-India quadrivalent HPV vaccine (Cervavac by Serum Institute of India) |
| Dosage | Single dose (following WHO’s 2022 recommendation for single-dose efficacy) |
| Delivery | Through schools and Anganwadi centres via Universal Immunisation Programme (UIP) |
| Cost | Free under government programme; market price ~Rs 2,000-4,000 per dose |
Cervavac — India’s Indigenous HPV Vaccine
Developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT):
- Type: Quadrivalent (targets HPV types 6, 11, 16, 18)
- HPV 16 and 18: Cause ~70% of cervical cancers globally
- HPV 6 and 11: Cause ~90% of genital warts
- Approval: DCGI approval received July 2022
- Significance: India becomes self-sufficient in HPV vaccine production, reducing dependence on Gardasil (Merck) and Cervarix (GSK)
The Screening Gap
Vaccination protects future generations, but the ~300 million women currently aged 30-65 remain unprotected — they need screening. India’s screening infrastructure is severely inadequate:
| Screening Method | Availability | WHO Recommendation |
|---|---|---|
| Pap smear | Limited to urban hospitals; requires trained cytologists | Every 3 years (age 21-65) |
| VIA (Visual Inspection with Acetic Acid) | Available at PHCs; lower sensitivity | Every 5 years |
| HPV DNA test | Most accurate; available only at tertiary centres | Preferred method; every 5-10 years |
The editorial recommends HPV DNA testing as the primary screening tool — it can be self-collected, processed in batched labs, and has the highest sensitivity (~95%) for detecting high-risk HPV infections before they progress to cancer.
WHO 90-70-90 Targets (by 2030)
The WHO Global Strategy to Eliminate Cervical Cancer sets three targets:
- 90% of girls fully vaccinated with HPV vaccine by age 15
- 70% of women screened with a high-performance test by age 35 and again by 45
- 90% of women with cervical disease receiving treatment
India’s current status against these targets:
- Vaccination: Campaign just launched (February 2026) — coverage <5%
- Screening: <2% coverage (target: 70%)
- Treatment: ~60-70% of diagnosed cases receive treatment (target: 90%)
Vaccine Hesitancy
The editorial notes that vaccine hesitancy — fuelled by misinformation about HPV vaccine causing infertility — remains a significant barrier. The 2009 PATH-ICMR HPV vaccine trial controversy (deaths during trial in Andhra Pradesh and Gujarat led to a Parliamentary Committee inquiry) continues to cast a shadow over HPV vaccination acceptance in India.
UPSC Relevance
Prelims: HPV types 16/18, Cervavac manufacturer (SII), WHO 90-70-90 targets, cervical cancer statistics, UIP
Mains GS-2: Health policy — vaccination programmes, screening infrastructure, rural-urban health disparities, women’s health
Mains GS-3: Science & Technology — indigenous vaccine development, public health innovation
📌 Facts Corner — Knowledgepedia
Cervical Cancer in India:
- New cases: ~1.2 lakh/year; deaths: ~79,000/year
- India’s share of global cases: ~23%
- Screening coverage: <2% of eligible women
- Cause: HPV (Human Papillomavirus) — types 16 and 18 cause ~70% of cases
HPV Vaccination (India):
- National programme launched: February 28, 2026
- Vaccine: Cervavac (Serum Institute of India, quadrivalent)
- Target: Girls aged 14; single dose; via UIP
- HPV types covered: 6, 11, 16, 18
- WHO single-dose recommendation: April 2022
WHO 90-70-90 Targets:
- 90% vaccination by age 15
- 70% screening by age 35 and 45
- 90% treatment for cervical disease
- Timeline: By 2030
Other Relevant Facts:
- SII: World’s largest vaccine manufacturer by volume (Pune)
- DBT: Department of Biotechnology (co-developed Cervavac)
- PATH-ICMR trial controversy: 2009; led to Parliamentary inquiry
- VIA: Visual Inspection with Acetic Acid — low-cost screening at PHCs
- HPV DNA test: Gold standard; ~95% sensitivity; self-collection possible